Aeolus Pharmaceuticals Inc. (OTCQB: AOLS) is developing its lead compound, AEOL – 10150, as a treatment for the lung effects of Acute Radiation Syndrome under a $118MM, 5 year contract from the Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services. The BARDA contract funds the development of AEOL – 10150 through FDA approval under the Animal Rule. If the development program is successful, AEOL – 10150 would be a candidate for procurement into the U.S. Strategic National Stockpile as a medical countermeasure for Lung-ARS. SNNLive spoke with David Cavalier, Chairman of Aeolus Pharmaceuticals Inc. at the LD Micro Invitational 2014 in Bel Air, CA.
“Aeolus is a drug company that’s developing treatment for exposure to radiation following a nuclear event under contract with the U.S. government,” begins Mr. Cavalier. He continues, “We also have funding from the National Institutes of Health for exposure to chemical gases and nerve gases, so we have a fairly diverse program of biodefense assets that’s going right now.”
Mr. Cavalier explains, “This drug will be developed under what’s called the FDA animal rule, which allows you to use animal studies in place of human studies because you can’t ethically do human studies.” He adds, “Purchases are made prior typically to FDA approval using a mechanism called the emergency-use authorization which allows drugs to be used as if approved in a declared emergency.” For more information, check out their website at www.aolsrx.com.
© 2017 Stock News Now
Supported by Superior Web Solutions